207-112-0

应用筛选条件

关键词:'207-112-0'

显示 1-3 共 3 条结果关于 "207-112-0" 范围论文

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Rodney Dawson et al.

Lancet (London, England), 385(9979), 1738-1747 (2015-03-22)

New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Josef S Smolen et al.

Lancet (London, England), 383(9914), 321-332 (2013-10-31)

Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early

Structural and Functional Lung Impairment in Adult Survivors of Bronchopulmonary Dysplasia.

Steven Caskey et al.

Annals of the American Thoracic Society, 13(8), 1262-1270 (2016-05-26)

As more preterm infants recover from severe bronchopulmonary dysplasia (BPD), it is critical to understand the clinical consequences of this condition on the lung health of adult survivors. To assess structural and functional lung parameters in young adult BPD survivors

1/1